ZYBERNO
Stock Report
Updated Jun 9, 2026

BIOLASE, INC. (BIOLQ)

Healthcare • Over The Counter

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
BIOLASE, INC. (BIOLQ) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-29.4%)
Return on Capital (Capital Efficiency):CRITICAL (-43.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BIOLASE, INC. (BIOLQ) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, BIOLQ generated -$15.10M in Owner Earnings. Capital was deployed as follows: $724.00K invested in capital expenditures. Reinvestment rate: 14.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$36.08

Valuation Multiples (2)

P/S Ratio:0.00x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$28.64M
B. Profitability Assessment

Return Metrics (4)

ROA:-50.4%
Reinvestment Rate:14.7%
Fundamental Growth Rate (g):-6.4%

Margin Analysis (3)

Operating Margin Ttm:-29.4%
Net Margin Ttm:-34.8%
Ebitda Margin:-23.7%

TTM Performance (3)

Gross Margin Ttm:34.4%
Operating Margin Ttm:-29.4%
Net Margin Ttm:-34.8%

Yield Metrics (2)

Earnings Yield:-$1.69B
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:99.2%
Latest Earnings Filed:2024-11-07

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):7.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.63x
Quick Ratio:0.31x
Cash Ratio:0.11x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-7.47x
Times Interest Earned:-7.47

Capital Structure (4)

Working Capital:-11,431,000.00
Cash And Cash Equivalents:3,444,000.00
Long Term Debt:$16.04M
Net Debt:$28.64M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $46.03M
Linear Growth: 7.9%
📊 Click to view full BIOLQ Revenue analysis & methodology →
Cost Of Revenue Ttm:$30.18M

Profitability Breakdown (2)

Gross profit TTM: $15.85M
Linear Growth: 9.4%
📊 Click to view full BIOLQ Gross Profit analysis & methodology →
-$13.52M

Bottom Line Performance (3)

-$16.04M
Income Before Tax:-$16.00M
Ebitda Ttm:-10,893,000.00

Operating Expenses (5)

Operating Expenses:29,368,000.00
R And D Expense:4,922,000.00
Sga Expense:10,264,000.00
Income Tax Expense:$67.00K
Interest Expense:2,400,000.00

Expense Ratios (3)

R And D To Revenue Percentage:45.4%
Sga To Revenue Percentage:94.6%
Ebitda Margin:-23.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$27.24M
Current Assets:$19.43M
Ppe Net:3,658,000.00
Goodwill:2,926,000.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:32,122,000.00
Current Liabilities:30,859,000.00
Long Term Debt:$16.04M
Short Term Debt:$16.04M

Equity & Capital (3)

Equity:-$5.23M
Retained Earnings:-$327.51M
Common Stock:180,000,000.00

Working Capital Items (3)

Accounts Receivable:3,530,000.00
Inventory:9,870,000.00
Accounts Payable:3,001,000.00

Special Items (2)

Contract Liabilities:2,446,000.00
Stock Based Compensation:51,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$14.37M-$15.10M

Investment Activities (2)

Investing Cash Flow:$197.00K
Capital Expenditures Ttm:724,000.00

Financing Activities (3)

Financing Cash Flow:$5.65M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:2,784,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,625,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-16.92
-$16.92
Earnings Per Share Ttm:-$0.44

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.28
Operating Cash Flow Per Share:-$0.39

Book Value & Capital (2)

Book Value Per Share:-$0.14
Cash Per Share:0.10

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.45x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:13.04x
Days Sales Outstanding Ttm:27.99

Inventory Management (2)

Inventory Turnover Ttm:3.06x
Days Inventory Outstanding Ttm:119.38

Payables & Cash Cycle (2)

Days Payable Outstanding:36.30
Cash Conversion Cycle:111.08
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$15.10M

Damodaran Growth Analysis (2)

Reinvestment Rate:14.7%
Fundamental Growth Rate (g):-6.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):7.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):9.4%
Book Value Growth Rate (Linear):-35.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:BIOLQ
Company Name:BIOLASE, INC.
Sector:Healthcare
Industry:Dental Equipment & Supplies
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:36.08M
Shares Outstanding Basic:36.08M
Shares Outstanding Diluted:36.08M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-09 00:53:22 UTC
Data Timestamp:2026-06-09T00:53:22.885243
Scroll to Top